SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 425 - Prospectuses and communications, business combinations:
SEC Accession No. 0001193125-21-171098
Filing Date
2021-05-24
Accepted
2021-05-24 17:22:30
Documents
7

Document Format Files

Seq Description Document Type Size
1 425 d117850d425.htm 425 21660
2 GRAPHIC g117850g0525020109158.jpg GRAPHIC 33680
3 GRAPHIC g117850g0525020109410.jpg GRAPHIC 3336
4 GRAPHIC g117850g0525020109574.jpg GRAPHIC 3829
5 GRAPHIC g117850g0525020109843.jpg GRAPHIC 15951
6 GRAPHIC g117850g0525020110198.jpg GRAPHIC 70336
7 GRAPHIC g117850g0525020110480.jpg GRAPHIC 98873
  Complete submission text file 0001193125-21-171098.txt   335482
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filed by) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 425
SIC: 2834 Pharmaceutical Preparations

Mailing Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053
Business Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053 (610) 254-9200
Strongbridge Biopharma plc (Subject) CIK: 0001634432 (see all company filings)

IRS No.: 981130690 | State of Incorp.: L2
Type: 425 | Act: 34 | File No.: 001-37569 | Film No.: 21956218
SIC: 2834 Pharmaceutical Preparations